JP2013517773A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517773A5
JP2013517773A5 JP2012550162A JP2012550162A JP2013517773A5 JP 2013517773 A5 JP2013517773 A5 JP 2013517773A5 JP 2012550162 A JP2012550162 A JP 2012550162A JP 2012550162 A JP2012550162 A JP 2012550162A JP 2013517773 A5 JP2013517773 A5 JP 2013517773A5
Authority
JP
Japan
Prior art keywords
fragment
chimeric protein
heterologous antigen
amino acids
norovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517773A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022094 external-priority patent/WO2011091279A2/en
Publication of JP2013517773A publication Critical patent/JP2013517773A/ja
Publication of JP2013517773A5 publication Critical patent/JP2013517773A5/ja
Pending legal-status Critical Current

Links

JP2012550162A 2010-01-21 2011-01-21 カリシウイルスウイルス様粒子上の標的化異種抗原提示 Pending JP2013517773A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29710910P 2010-01-21 2010-01-21
US61/297,109 2010-01-21
PCT/US2011/022094 WO2011091279A2 (en) 2010-01-21 2011-01-21 Targeted heterologous antigen presentation on calicivirus virus-like particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000115A Division JP2016106101A (ja) 2010-01-21 2016-01-04 カリシウイルスウイルス様粒子上の標的化異種抗原提示

Publications (2)

Publication Number Publication Date
JP2013517773A JP2013517773A (ja) 2013-05-20
JP2013517773A5 true JP2013517773A5 (enExample) 2014-03-13

Family

ID=44307607

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012550162A Pending JP2013517773A (ja) 2010-01-21 2011-01-21 カリシウイルスウイルス様粒子上の標的化異種抗原提示
JP2016000115A Pending JP2016106101A (ja) 2010-01-21 2016-01-04 カリシウイルスウイルス様粒子上の標的化異種抗原提示

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016000115A Pending JP2016106101A (ja) 2010-01-21 2016-01-04 カリシウイルスウイルス様粒子上の標的化異種抗原提示

Country Status (9)

Country Link
US (2) US8980275B2 (enExample)
EP (1) EP2525816A4 (enExample)
JP (2) JP2013517773A (enExample)
KR (1) KR20120125627A (enExample)
CN (1) CN102791286B (enExample)
AU (1) AU2011207355B2 (enExample)
CA (1) CA2787666A1 (enExample)
SG (1) SG182636A1 (enExample)
WO (1) WO2011091279A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
HUE028605T2 (en) * 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) * 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014145245A2 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
US10744193B2 (en) 2015-03-30 2020-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic RSV polypeptides
JP6675185B2 (ja) * 2015-11-30 2020-04-01 宏 半田 免疫誘導剤およびその製造方法
WO2017191264A1 (en) * 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
US11608361B2 (en) 2017-03-23 2023-03-21 Medicago Inc. Norovirus fusion proteins and VLPS comprising norovirus fusion proteins
CN107988240A (zh) * 2017-12-20 2018-05-04 中国人民解放军南京军区南京总医院 鼠诺如病毒vp1蛋白病毒样颗粒表达、纯化及多克隆抗体制备
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
CN116063578A (zh) * 2022-11-22 2023-05-05 中国医学科学院医学生物学研究所 一种以诺如病毒衍生的纳米颗粒作为疫苗平台的制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
JPH08500250A (ja) * 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
EP1186890B1 (en) 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
WO2006138514A2 (en) 2005-06-16 2006-12-28 Children's Hospital Medical Center Novel norovirus particle for use as an antiviral or vaccine
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
AU2007304883B2 (en) * 2006-10-04 2013-09-05 The University Of Queensland VLP based vaccine delivery system
JP5894528B2 (ja) * 2009-06-09 2016-03-30 チルドレンズ ホスピタル メディカル センター 抗原−ノロウイルスpドメインモノマーおよびダイマー、抗原−ノロウイルスp粒子分子、ならびにそれらの製造および使用法
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles

Similar Documents

Publication Publication Date Title
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
Hadj Hassine et al. Virus‐like particles as powerful vaccination strategy against human viruses
JP2014532691A5 (enExample)
JP2015524422A5 (enExample)
JP2014507144A5 (ja) 慢性b型肝炎感染症のための酵母系免疫療法組成物
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP2013216685A5 (enExample)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
JP2013533745A5 (enExample)
WO2010118424A3 (en) Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
Valero-Pacheco et al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine
JP2013523686A5 (enExample)
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
JP2023024998A5 (enExample)
JP2014519817A5 (enExample)
Raji et al. Virus-like particles in poultry disease: an approach to effective and safe vaccination
RU2022108149A (ru) Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
Jia et al. Delivery of dendritic cells targeting 3M2e-HA2 nanoparticles with a CpG adjuvant via lysosomal escape of Salmonella enhances protection against H9N2 avian influenza virus
HK1212708A1 (zh) H1n1流感的計算優化的寬反應性抗原
JP2016528176A5 (enExample)
JP2016505538A5 (enExample)
Chen et al. Recombinant bacteriophage T4 displaying key epitopes of the foot-and-mouth disease virus as a novel nanoparticle vaccine
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
WO2016026401A1 (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用